There are a 1/2 dozen PD-1 PDL-1 inhibitors on the market right now. Keytruda is number 1 with over 10B in sales last year PDL-1 inhibitors are already 25-40B a year segment in cancer treatments and growing fast. Merck has 75 different cancer trials going with Keytruda trying to increase which cancers it is the SOC, and of course increase market share.
My theory is that they would probably work even better together. Even the best treatments are only about 30% effective on some cancers and only about 5-15% are complete remissions. Treating cancer is a multi drug proposition and a drug that does not add to the SAEs is gold. Can be given to everybody.